ArticleLa Tunisie medicale2025
A ten-year hemovigilance report in the regional blood transfusion center of Sfax (Tunisia).
Article in La Tunisie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn Tunisia, despite hemovigilance regulations since 2007, transfusion adverse events (TAEs) remain underreported. Here, we analyze and evaluate the reported TAEs over ten years in the blood transfusion center of Sfax (Tunisia).
methodsThis is a ten-year (2012-2021) descriptive and exhaustive report on TAE from the second largest blood center in Tunisia, where around 56,000 labile blood products are issued annually.
resultsFour-hundred-sixty-four TAEs were reported. The median age of the patients was 38 years (1 month to 94 years). The sex ratio was 0.68. The overall TAE annual incidence per issued labile blood product was 0.77‰ and ranged from 0.47 to 1.43‰. The most common TAE was a febrile non-hemolytic reaction (31.7%), followed by an allergic reaction (21.6%). The severity degree was informed in 433 cases (93.3%). Grade 1 severity was the most common (80.8%), followed by grades 3, 2 and 4 (10.6%, 1.3% and 0.6%, respectively). Packed red blood cells were the most implicated labile blood product (81.5%). Standard platelet concentrates and fresh frozen plasma accounted for 6.5% and 5% of the total adverse transfusion reactions, respectively.
conclusionThe TAE incidence in our study seems to be underestimated compared to worldwide reported TAEs. The analysis of reported TAEs in our context illustrates the insufficiency of the regulation's implementation alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.